Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(271 sites)

United States

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Anchorage Associates in Radiation Medicine, Anchorage, Alaska

Anchorage Radiation Therapy Center, Anchorage, Alaska

Alaska Breast Care and Surgery LLC, Anchorage, Alaska

Alaska Oncology and Hematology LLC, Anchorage, Alaska